Evidence verdict: One, three and six months can be useful review points. They are not a validated universal timetable for improvement after MSC therapy across different diseases and products.
Patients deserve a follow-up plan before treatment, including what will be measured, who will interpret it, and how concerns will be handled. A plan should allow for improvement, no meaningful change, and deterioration.
Before treatment: record a usable baseline
Agree with the treating clinician on the diagnosis, one or two meaningful goals, and the appropriate measurement tools. Record symptoms, relevant function, medications and concurrent care. Ask for a written product and procedure record and clear contact instructions.
The following schedule is an educational discussion framework, not a substitute for a condition-specific care plan.
At one month: review safety and early change
Compare the same measures with baseline. Record adverse events and changes in medications or rehabilitation. Avoid concluding that an early improvement proves cell engraftment or that lack of improvement means the treatment is still quietly regenerating tissue.
At three months: evaluate meaningful benefit
Ask whether any change matters in daily life and whether other care could explain it. If there is no benefit, reassess the diagnosis, treatment rationale and alternatives. Do not automatically label the patient a slow responder or assume a larger dose is required.
At six months: assess durability and the next decision
Document sustained benefit, loss of benefit, nonresponse and any problems. Imaging should answer a clinical question; it should not be ordered simply to provide a regeneration narrative. A repeat procedure needs its own justification, risks and cost discussion.
Why the original promises were too broad
The MILES knee trial illustrates why an improvement schedule cannot be inferred from treatment alone: its cell-based groups did not outperform corticosteroid at the primary one-year pain endpoints. Mautner et al., 2023. A study’s assessment date is not a promise about when an individual will recover.
Do not wait for a scheduled visit when something is wrong
Unapproved regenerative products have been associated with serious adverse events, including infections and unwanted immune reactions. New or worsening symptoms warrant clinical assessment rather than an assumption that they indicate healing. Follow your clinician’s urgent-care instructions and seek emergency help for severe symptoms. FDA patient safety information.
Continue prescribed care unless the responsible clinician advises a change. A useful follow-up process values honest nonresponse reporting as much as a positive story.
Disclosure: Dr. Ramon De La Puerta is affiliated with Z-Lounge Regenerative Medicine and has a commercial interest in regenerative-medicine services. This relationship should be considered when reading this article. The discussion is educational and does not determine whether a treatment is appropriate for an individual patient.
Correction — September 11, 2026: This revision replaces predicted gains at one, three and six months with assessment milestones. It removes a hypothetical success trajectory, broad regeneration claims and unsupported repeat-treatment assumptions.
